Get started
Author

Alexander H Philbrick

Observed names: A. Philbrick, Alexander Philbrick
ORCID: 0000-0001-5210-423X
Observed ORCID: 0000-0001-5210-423X
OpenAlex ID: A5013120381
Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations
2023 · Zachary M. Sellers, David N. Assis, et al. · Hepatology · 105
Faropenem Medoxomil
2007 · Jacob P Gettig, Christopher W Crank, et al. · Annals of Pharmacotherapy · 31
Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis
2022 · Brionna N. Hudson, Hollyann R. Jacobs, et al. · Journal of Cystic Fibrosis · 21
PDF
Efficacy of Ertapenem for Consolidation Therapy of Extended-Spectrum β-lactamase-Producing Gram-Negative Infections: A Case Series Report
2008 · Melody L Berg, Christopher W Crank, et al. · Annals of Pharmacotherapy · 20
Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis
2021 · Roxane Rohani, Brian Hoff, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 3
P-384. Discontinuation Patterns and Virologic Failure Among Persons with HIV Receiving Long-Acting Injectable Cabotegravir-Rilpivirine Antiretroviral Therapy
2026 · Sara M Hockney, Dana Mueller, et al. · Open Forum Infectious Diseases
768 Implementation of Cystic Fibrosis Foundation guidelines for screening, evaluation, and management of CF hepatobiliary disease and impact on patient care
2024 · A. Philbrick, K. Clemmons, et al. · Journal of Cystic Fibrosis
Works count: 7
Citation count: 180
H-index: 4
I10-index: 4
Year
Topic
Type